Clinical trial Recruiting at 1 site Observational Ages 6 and up

Using inflammation tests to improve asthma diagnosis in children and adults

Official title: PROPULSION SANTE: Inflammometry to Improve the Diagnostic Trajectory in Situations of Suspected Asthma in Children and Adults

Run by Université de Sherbrooke · NCT06981169 · Data updated 2026-11-12

This study is testing if measuring certain inflammation markers can help doctors diagnose asthma faster in children and adults who are suspected of having the condition.

More Asthma trials

Quick facts

Study typeObservational
Ages6 Years and up
SexAll
Enrollment1500 (estimated)
SponsorUniversité de Sherbrooke
Academic / other
Locations3 sites (Montreal, Quebec and 2 other locations)
StatusRecruiting
StartedMarch 24, 2025
Main results expectedDecember 1, 2026
Study endsJuly 1, 2027
Registry record updatedApril 30, 2026
Trial IDNCT06981169 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged six and older who have been referred by primary care for asthma diagnostic testing.

Probably not a fit

Patients referred by pulmonologists will not benefit from this study as they do not meet the inclusion criteria.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of inflammometry, specifically measuring fractional exhaled nitric oxide (FeNO) and blood eosinophil count (BEC), in prioritizing respiratory diagnostic tests for suspected asthma cases. It will include patients aged six and older who have been referred for diagnostic asthma testing at three hospital centers in Quebec. The hypothesis is that utilizing these biomarkers will reduce diagnostic delays for high-risk patients, thereby improving the overall diagnostic pathway and reducing wait times for necessary tests. The study seeks to address the current challenges in accessing timely asthma diagnostics, particularly for those with Type 2 eosinophilic inflammation.

Why it matters

Potential benefit: If successful, this approach could significantly shorten wait times for asthma diagnosis and improve patient outcomes by facilitating timely treatment.

How similar studies have gone: While the use of FeNO as a diagnostic tool is established in Europe, this specific approach in Quebec is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* patients age 6 and older
* referred by primary care ofr an asthma diagnostic test (spirometry or methacholine challenge)

Exclusion Criteria:

* referred by pulmonologist

Where it's running

  • CIUSSS de l'Estrie - CHUS
    Sherbrooke, Quebec, Canada
    Recruiting
  • CHU Sainte-Justine
    Montreal, Quebec, Canada
    Not yet recruiting
  • Montreal Children's Hospital
    Montreal, Quebec, Canada
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.